AOM Infusion, known nationally for its specialty infusion and pharmacy services that support people managing chronic and complex medical needs, has been selected by Kedrion Biopharma to join the limited distribution network for YIMMUGO (Immune Globulin Intravenous, Human-dira, 10%). This addition strengthens AOM’s portfolio of IVIG therapies and expands access to an important treatment option for patients with primary humoral immunodeficiency (PI).
Health Technology Insights: TurnOnGreen to Power New High-Precision Medical Laser
YIMMUGO is a 10% immune globulin therapy approved for patients aged two and older with primary humoral immunodeficiency, including conditions such as congenital agammaglobulinemia, common variable immunodeficiency, and severe combined immunodeficiencies. Treatment is typically administered every three to four weeks by a trained clinician either at home or in an AOM Infusion center, with dosing tailored to each patient’s weight and response to therapy.
Kedrion Biopharma selected AOM Infusion based on its nationwide service model and long-standing expertise in IVIG therapies that span more than 80 chronic and rare conditions. The company has built a reputation for providing consistent, knowledgeable support for patients with PI and the physicians who manage their care.
Health Technology Insights: Lipocine Reports Positive Phase 3 Safety for LPCN 1154
Bob Rossilli, Chief Commercial Officer at Kedrion Biopharma Inc., noted that AOM’s strong patient focus and high operational standards made the company a natural fit for the limited distribution network. In his view, working with AOM strengthens the ability to deliver dependable access to essential immunoglobulin therapies for patients across the country.
AOM Infusion regularly evaluates new Ig products to ensure patients can receive advanced therapies without unnecessary delays. Its teams support physicians and patients through every step of treatment—from clinical oversight and scheduling to coordination with insurers and collection of outcomes data.
Karmen Stowe, Vice President of Trade Relations & Supply Chain at AOM Infusion, expressed appreciation for the confidence Kedrion placed in their organization. She explained that AOM’s three decades of experience with immunoglobulin therapies allow the team to make thoughtful decisions about which products best meet a patient’s individual needs. Her focus remains on helping people achieve better health outcomes and maintain a higher quality of life through reliable, well-supported infusion care.
With its new role as a limited-distribution specialty pharmacy for YIMMUGO, AOM Infusion expands its IVIG capabilities even further and reinforces its commitment to improving timely access to vital treatments in partnership with clinicians, health systems, and payors across the United States.
Health Technology Insights: InteliChart Launches InteliSense to Power a New Era of Patient Engagement
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
